# US 2026/0008780 A1 · Substituted 3,4-dihydroisoquinolin-1(2h)-one derivatives and related uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0008780 A1
- Document ID: US20260008780A1
- Status: Published application
- Kind: A1
- Application number: 18/872,082
- Filed: 2023-06-07
- Published: 2026-01-08
- Earliest claimed: 2022-06-07
- Assignees: NodThera Limited
- Applicants: NodThera Limited
- Inventors: Mark G. BOCK; David HARRISON; Jane E. SCANLON
- Web page: https://patentgrep.com/patent/US20260008780A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 513/14: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

## Claims

### Claim 1

A compound of Formula (I):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof, wherein:
each is independently a single bond or double bond as valency allows;
A2 is CR2, N, NR2a, O, or S, as valency allows;
A3 is CR2, N, NR2a, O, or S, as valency allows;
A4 is CR2, N, NR2a, O, or S, as valency allows;
A5 is C or N, as valency allows,
wherein at least one of A2, A3, A4, or As is N, NR2a, O, or S;
R1 is H, —N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C3-C12 cycloalkyl, wherein the —N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C3-C12 cycloalkyl is optionally substituted with one or more R1S;
each R1S independently is halogen, cyano, —OH, or C1-C6 alkyl;
R1a is H or C1-C6 alkyl, or
R1 and R1a together with the atoms to which they are attached form C2-C6 alkenyl, C3-C7 cycloalkyl, or 3- to 7-membered heterocycloalkyl, or
R1a and R3 together with the atoms to which they are attached form a C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl;
each R2 independently is H, halogen, cyano, —OH, —NH2, —NO2, —C(═O)NH2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R2S,
or two R2 together with the atoms to which they are attached form a C3-C12 cycloalkyl, 3-to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R2S;
each R2S independently is halogen, C1-C6 alkyl, —OH, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or C3-C12 cycloalkyl;
R3 is H, —N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C3-C12 cycloalkyl, wherein the —N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C3-C12 cycloalkyl is optionally substituted with one or more R1S, or
R1 and R3 together with the atoms to which they are attached form a C3-C12 cycloalkyl or 3- to 12-membered heterocycloalkyl;
each R1S independently is halogen, cyano, —OH, or C1-C6 alkyl;
each R2a independently is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, —(CH2)0-3—(C3-C12 cycloalkyl), or —(CH2)0-3-(3- to 12-membered heterocycloalkyl);
each Ra independently is H or C1-C6 alkyl; or two Ra, together with the atom they attach to, form C2-C6 alkenyl or C3-C12 cycloalkyl;
RN1 is H or C1-C6 alkyl;
RN2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O—(C1-C6 alkyl), —O—(C2-C6 alkenyl), —O—(C2-C6 alkynyl), —NH—(C1-C6 alkyl), —NH—(C2-C6 alkenyl), —NH—(C2-C6 alkynyl), C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl); wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O—(C1-C6 alkyl), —O—(C2-C6 alkenyl), —O—(C2-C6 alkynyl), —NH—(C1-C6 alkyl), —NH—(C2-C6 alkenyl), —NH—(C2-C6 alkynyl), C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl) is optionally substituted with one or more RN2a;
each RN2a independently is oxo, halogen, cyano, —OH, —NH2, —NO2, —C(═O)H, —C(═O)OH, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)(C1-C6 alkyl), —C(═O)O(C1-C6 alkyl), —NHC(═O)O(C1-C6 alkyl), —S(═O)2(C1-C6 alkyl), —S(═O)2N(C1-C6 alkyl)2, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl); wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)(C1-C6 alkyl), —C(═O)O(C1-C6 alkyl), —NHC(═O)O(C1-C6 alkyl), —S(═O)2(C1-C6 alkyl), —S(═O)2N(C1-C6 alkyl)2, C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, 5- to 10-membered heteroaryl, —(C1-C6 alkyl)-(C3-C12 cycloalkyl), —(C1-C6 alkyl)-(3- to 12-membered heterocycloalkyl), —(C1-C6 alkyl)-(C6-C10 aryl), or —(C1-C6 alkyl)-(5- to 10-membered heteroaryl) is optionally substituted with one or more RN2ab; and
each RN2ab independently is oxo, halogen, cyano, —OH, —NH2, —C(═O)H, —C(═O)OH, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)(C1-C6 alkyl), —C(═O)O(C1-C6 alkyl), —NHC(═O)O(C1-C6 alkyl), —S(═O)2(C1-C6 alkyl), or —S(═O)2N(C1-C6 alkyl)2; or
RN1 and RN2, together with the atom they attach to, form 3- to 12-membered heterocycloalkyl optionally substituted with one or more Rb;
each Rb independently is oxo, halogen, cyano, —OH, —NH2, —C(═O)H, —C(═O)OH, C1-C6 alkyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)(C1-C6 alkyl), —C(═O)O(C1-C6 alkyl), —NHC(═O)O(C1-C6 alkyl), —S(═O)2(C1-C6 alkyl), or —S(═O)2N(C1-C6 alkyl)2, wherein the C1-C6 alkyl, —O(C1-C6 alkyl), —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —C(═O)(C1-C6 alkyl), —C(═O)O(C1-C6 alkyl), —NHC(═O)O(C1-C6 alkyl), —S(═O)2(C1-C6 alkyl), or —S(═O)2N(C1-C6 alkyl)2 is optionally substituted with one or more Rb1; and
each Rb1 independently is oxo, halogen, cyano, —OH, or —NH2.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
A2 is CR2, A3 is CR2, A4 is CR2, and A5 is N, optionally wherein the CR2 of A3 and A4 join to form a thienyl or thiazolyl ring; or
A2 is CR2, A3 is NR2a, A4 is N, and A5 is C; or
A2 is CR2, A3 is CR2, A4 is N, and A5 is N; or
A2 is S, A3 is CR2, A4 is N, and A5 is C; or
A2 is S, A3 is CR2, A4 is CR2, and A5 is C; or
A2 is CR2, A3 is CR2, A4 is O, and A5 is C; or
A2 is NR2a, A3 is CR2, A4 is CR2, and A5 is C; or
A2 is NR2a, A3 is CR2, A4 is N, and A5 is C; or
A2 is CR2, A3 is CR2, A4 is S, and A5 is C;
wherein R2 and R2a are as defined in claim 1.

### Claim 3

The compound of any one of the preceding claims, wherein R1 is H.

### Claim 4

The compound of any one of the preceding claims, wherein R1a is H or methyl.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein:
R1 is H and R1a is H; or
R1 is C1-C6 alkyl and R1a is H; or
R1 is H and R1a is C1-C6 alkyl; or
R1 is methyl and R1a is H; or
R1 is H and R1a is methyl; or
R1 and R1a together with the atoms to which they are attached form C3-C7 cycloalkyl; or
R1 and R1a together with the atoms to which they are attached form cyclopropyl.

### Claim 6 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein R1 and R1a together with the atoms to which they are attached form C3-C7 cycloalkyl.

### Claim 7

The compound of any one of the preceding claims, wherein R2 is H, C1-C6 alkyl, —O—(C1-C6 alkyl), —NH—(C1-C6 alkyl), or C3-C12 cycloalkyl, or two R2 together with the atoms to which they are attached form 5- to 10-membered heteroaryl optionally substituted with one or more R2S.

### Claim 8

The compound of any one of the preceding claims, wherein at least one R2S is halogen or C1-C6 alkyl.

### Claim 9

The compound of any one of the preceding claims, wherein R2a is H or C1-C6 alkyl.

### Claim 10

The compound of any one of the preceding claims, wherein:
R3 is H; or
R3 is C1-C6 alkyl; or
R3 is methyl; or
R3 and R1a together with the atoms to which they are attached form C3-C7 cycloalkyl; or
R3 and R1a together with the atoms to which they are attached form cyclopropyl; or
R3 and R1 together with the atoms to which they are attached form C3-C7 cycloalkyl; or
R3 and R1 together with the atoms to which they are attached form cyclopropyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein R1 and R3 together with the atoms to which they are attached form C3-C12 cycloalkyl.

### Claim 12

The compound of any one of the preceding claims, wherein at least one Ra is H.

### Claim 13

The compound of any one of the preceding claims, wherein both Ra are H.

### Claim 14

The compound of any one of the preceding claims, wherein RN1 is H.

### Claim 15

The compound of any one of the preceding claims, wherein RN2 is C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more RN2a.

### Claim 16

The compound of any one of the preceding claims, wherein RN2 is

### Claim 17

The compound of any one of the preceding claims, wherein at least one RN2a is oxo, F, Cl, cyano, —OH, —NH2, —NO2, methyl, CF3, —O(methyl), —C(═O)O(ethyl), or pyrazolyl.

### Claim 18 (depends on 1)

The compound of claim 1, wherein:
A2 is CR2, NR2a, or S;
A3 is CR2, NR2a, or O;
A4 is CR2, S, or O;
A5 is C or N;
wherein at least one of A2, A3, A4, or A5 is N, NR2a, O, or S;
R1 is H;
R1a is H or C1-C6 alkyl, or
R1 and Ra together with the atoms to which they are attached form C3-C7 cycloalkyl, or
R1a and R3 together with the atoms to which they are attached form a C3-C12 cycloalkyl;
each R2 independently is H, C1-C6 alkyl, —O—(C1-C6 alkyl), —NH—(C1-C6 alkyl), or C3-C12 cycloalkyl,
or two R2 together with the atoms to which they are attached form a 5- to 10-membered heteroaryl optionally substituted with one or more R2S; each R2S independently is halogen or C1-C6 alkyl;
each R2a independently is H or C1-C6 alkyl;
R3 is H or C1-C6 alkyl;
each Ra independently is H;
RN1 is H;
RN2 is C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl; wherein the C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R2a; and
each RN2a independently is halogen, —OH, C1-C6 alkyl, —C(═O)O(C1-C6 alkyl), or C3-C12 cycloalkyl.

### Claim 19 (depends on 1, 18)

The compound of claim 1 or claim 18, wherein:
A2 is CR2, NR2a, or S;
A3 is CR2, NR2a, or 0;
A4 is CR2, N, S, or O;
A5 is C or N;
wherein at least one of A2, A3, A4, or A5 is N, NR2a, O, or S;
R1 is H;
R1a is H or methyl, or
R1 and R1a together with the atoms to which they are attached form cyclopropyl, or
R1a and R3 together with the atoms to which they are attached form a cyclobutyl;
each R2 independently is H, methyl, ethyl, isopropyl, cyclopropyl, —NH-ethyl, or —O-ethyl,
or two R2 together with the atoms to which they are attached form a thienyl or thiazolyl ring optionally substituted with one or more R2S;
each R2S independently is chlorine or methyl;
each R2a independently is H, methyl, ethyl or isopropyl;
R3 is H or methyl;
each Ra independently is H;
RN1 is H;
RN2 is cyclobutyl, piperidinyl, oxaspiro[3.3]heptanyl, thiadiazolyl, or pyrimidinyl, each of which is optionally substituted with one or more RN2a and
each RN2a independently is fluorine, —OH, methyl, —C(═O)O(ethyl), or cyclobutyl.

### Claim 20

The compound of any one of the preceding claims, wherein the compound is of Formula (II):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i), (I-j), (I-k), (I-l), (I-m), (I-n), (I-o), (I-p), (I-q), (I-r), (I-s), (I-t), (I-u), (I-v), (I-w), (I-x), (I-yl), (I-z), (I-aa), (I-ab), (I-ac), (I-ad), (I-ae), (I-af), or (I-ag):
or a prodrug, solvate, or pharmaceutically acceptable salt thereof.

### Claim 22

The compound of any one of the preceding claims, wherein the compound is selected from the compounds described in Table 1, or a prodrug or pharmaceutically acceptable salt thereof.

### Claim 23

A compound being an isotopic derivative of the compound of any one of the preceding claims.

### Claim 24

A compound obtainable by, or obtained by, a method described herein.

### Claim 25

A pharmaceutical composition comprising the compound of any one of the preceding claims and a pharmaceutically acceptable diluent or carrier.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of inhibiting inflammasome activity, comprising contacting a cell with a compound of any one of claims 1-24; optionally, the inflammasome is NLRP3 inflammasome, and the activity is in vitro or in vivo.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-24 or pharmaceutical composition of claim 25, for use in inhibiting inflammasome activity; optionally, wherein the inflammasome is NLRP3 inflammasome, and the activity is in vitro or in vivo.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the compound of any one of claims 1-24 in the manufacture of a medicament for inhibiting inflammasome activity; optionally, the inflammasome is NLRP3 inflammasome, and the activity is in vitro or in vivo.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of treating or preventing a disease or disorder in a subject in need thereof, comprising administering to the subject a compound of any one of claims 1-24, or the pharmaceutical composition of claim 25.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-24 or pharmaceutical composition of claim 25, for use in treating or preventing a disease or disorder.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of the compound of any one of claims 1-24 in the manufacture of a medicament for treating or preventing a disease or disorder.

### Claim 32 (depends on 29, 30, 31)

The method, compound, pharmaceutical composition, or use of any one of claims 29-31, wherein the disease or disorder is associated with an implicated inflammasome activity; optionally, the disease or disorder is a disease or disorder in which inflammasome activity is implicated.

### Claim 33 (depends on 29, 30, 31, 32)

The method, compound, pharmaceutical composition, or use of any one of claims 29-32, wherein the disease or disorder is an inflammatory disorder, an autoinflammatory disorder, an autoimmune disorder, a neurodegenerative disease, or cancer.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The method, compound, pharmaceutical composition, or use of any one of claims 29-33, wherein the disease or disorder is an inflammatory disorder, an autoinflammatory disorder or an autoimmune disorder; optionally, the disease or disorder is selected from cryopyrin-associated auto-inflammatory syndrome (CAPS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome/neonatal-onset multisystem inflammatory disease (NOMID)), familial Mediterranean fever (FMF), nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gout, rheumatoid arthritis, osteoarthritis, Crohn's disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), fibrosis, obesity, type 2 diabetes, multiple sclerosis, dermatological disease and neuroinflammation occurring in protein misfolding diseases.

### Claim 35 (depends on 29, 30, 31, 32, 33)

The method, compound, pharmaceutical composition, or use of any one of claims 29-33, wherein disease or disorder is a neurodegenerative disease; optionally, the disease or disorder is Parkinson's disease or Alzheimer's disease.

### Claim 36 (depends on 29, 30, 31, 32, 33)

The method, compound, pharmaceutical composition, or use of any one of claims 29-33, wherein the disease or disorder is cancer; optionally, the cancer is metastasising cancer, brain cancer, gastrointestinal cancer, skin cancer, non-small-cell lung carcinoma, head and neck squamous cell carcinoma or colorectal adenocarcinoma.

### Claim 37 (depends on 29, 30, 31, 32, 33)

The method, compound, pharmaceutical composition, or use of any one of claims 29-33, wherein the disease or disorder is an inflammatory disease.

### Claim 38 (depends on 37)

The method, compound, pharmaceutical composition, or use of claim 37, wherein the inflammatory disease is associated with an infection, optionally wherein the infection is a viral infection.

### Claim 39 (depends on 38)

The method, compound, pharmaceutical composition, or use of claim 38, wherein the viral infection is caused by a single stranded RNA virus, optionally wherein the single stranded RNA virus is a coronavirus.

### Claim 40 (depends on 37)

The method, compound, pharmaceutical composition or use of claim 37, wherein the inflammatory disease comprises cytokine release syndrome (CRS).

### Claim 41 (depends on 40)

The method, compound, pharmaceutical composition, or use of claim 40, wherein the CRS is associated with COVID-19 or an adoptive cell therapy.

### Claim 42 (depends on 41)

The method, compound, pharmaceutical composition, or use of claim 41, wherein the adoptive cell therapy comprises chimeric antigen receptor T cell (CAR-T) therapy.
